Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered

Editas Medicine, Inc.

2025-Q2 EPS reported -$1.54 vs consensus -$0.38 ▼ miss (-300.4%)

Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.
Cash $178.5M at June 30 (down from $269.9M at Dec 2024); runway into Q2 2027.
R&D expense fell $38M to $16.2M on reni-cel discontinuation; restructuring charges $26.1M.
First IND/CTA accepted for CD19 HD Allo CAR T with BMS, triggering milestone payment to Editas.
On track to name lead in vivo candidate Sept 2025, file IND mid-2026, achieve POC by end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.